Program
sutezolid
Also written as “PNU-100480”, “BIA 5-1058 and Furosemide” and “Treatment C”.
Its studies are mostly in Tuberculosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, Type 2, led by 3 companies.
Drug pagePNU-100480: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sequellaits history only | 30 open or running | phase 2since Oct 19, 2010 | Mar 27, 2009 | none ahead |
| AJU Pharm | 10 open or running | phase 1since Jul 12, 2021 | Jul 12, 2021 | none ahead |
| Bial - Portela Cits history only | 10 open or running | phase 1since Sep 8, 2025 | Sep 8, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AJU Pharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2021First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04970940 · 30 enrolled · Korea, Republic of
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“70S ribosome inhibitor”ChEMBL 37, by rule
Studies
The one study AJU Pharm leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04970940Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Oct 7, 2020 | 30 |
How it is read
Names in the registry
- “PNU-100480”, 23 entries
- “BIA 5-1058 and Furosemide”, 1 entry
- “Treatment C”, 1 entry
Conditions, from the studies’ own filings
- Tuberculosis, 3 studies
- Pulmonary Arterial Hypertension, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.